Company Filing History:
2 out of 2,103 
1 out of 1 Years Active: 2006-2014
Title: André Lieber: Innovator in Gene Therapy and Complement Regulation
Introduction
André Lieber is a prominent inventor based in Seattle, WA, known for his significant contributions to the fields of gene therapy and complement regulation. With a total of 2 patents, Lieber has made strides in developing innovative methods and compositions that have the potential to impact medical treatments.
Latest Patents
Lieber's latest patents include "Compositions and methods for modulating the activity of complement regulatory proteins on target cells." This invention focuses on agents that can reduce the activity, amount, or density of complement regulatory proteins (CRPs) on target cells. The patent also outlines methods for identifying such agents, as well as methods for their production and applications. Another notable patent is "Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration." This invention provides novel chimeric adenoviral vectors that carry transgenes for stable and efficient gene transfer into various cell types or tissues, independent of CAR and αβ interactions. The patent also details methods for producing these vectors and their use in targeted gene therapy.
Career Highlights
Throughout his career, André Lieber has worked with esteemed institutions, including the University of Washington and Complement Corporation. His work has been instrumental in advancing the understanding and application of gene therapy techniques.
Collaborations
Lieber has collaborated with notable colleagues such as Dmitry M Shayakhmetov and Denise R Farrer, contributing to a rich environment of innovation and research.
Conclusion
André Lieber's work exemplifies the intersection of innovation and medical science, particularly in gene therapy and complement regulation. His patents reflect a commitment to advancing healthcare solutions through cutting-edge research and development.